Medicago and GSK announce promising mid-stage trial data for plant-derived COVID-19 vaccine

Interim results from phase II trial evaluating this vaccine candidate in combination with GSK’s pandemic adjuvant, found neutralising antibody responses were 10 times higher in vaccinated participants vs. people recovering from COVID-19, allowing move towards phase III trial.

Source:

PharmaTimes